Sarepta shares dive as gene therapy misses late-stage main goal

Sarepta Therapeutics

03/11/2025 21:38

** Shares in Sarepta Therapeutics SRPT.O slump nearly 21% to $5.1 in extended trading

** A late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet main goal

** Trial ran for nine years and was affected by the COVID-19 pandemic, which SRPT said impacted results

** Up to last close, stock had fallen ~80% this year

 (Reporting by Prerna Bedi in Bengaluru)

 ((Prerna.Bedi@thomsonreuters.com; +91 98052 24616;))